The Changing Landscape of Anticoagulation in Pediatric Extracorporeal Membrane Oxygenation: Use of the Direct Thrombin Inhibitors

Cindy Neunert, Meera Chitlur*, Cornelia Heleen van Ommen

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

1 Citation (Scopus)
1 Downloads (Pure)

Abstract

Bleeding and thrombosis frequently occur in pediatric patients with extracorporeal membrane oxygenation (ECMO) therapy. Until now, most patients are anticoagulated with unfractionated heparin (UFH). However, heparin has many disadvantages, such as binding to other plasma proteins and endothelial cells in addition to antithrombin, causing an unpredictable response, challenging monitoring, development of heparin resistance, and risk of heparin-induced thrombocytopenia (HIT). Direct thrombin inhibitors (DTIs), such as bivalirudin and argatroban, might be a good alternative. This review will discuss the use of both UFH and DTIs in pediatric patients with ECMO therapy.

Original languageEnglish
Article number887199
JournalFrontiers in Medicine
Volume9
DOIs
Publication statusPublished - 6 Jul 2022

Bibliographical note

Publisher Copyright:
Copyright © 2022 Neunert, Chitlur and van Ommen.

Fingerprint

Dive into the research topics of 'The Changing Landscape of Anticoagulation in Pediatric Extracorporeal Membrane Oxygenation: Use of the Direct Thrombin Inhibitors'. Together they form a unique fingerprint.

Cite this